trending Market Intelligence /marketintelligence/en/news-insights/trending/nX_24498_lIqHG7h7bqzuA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Momenta Pharmaceuticals to raise up to $230M from common stock offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Momenta Pharmaceuticals to raise up to $230M from common stock offering

Momenta Pharmaceuticals Inc. priced an underwritten public offering of its common stock to raise up to $230 million in gross proceeds.

The Cambridge, Mass.-based biotechnology company is offering $200 million worth of its shares. Underwriters will also receive an option to buy up to an additional $30 million of the company's common stock.

Goldman Sachs & Co. LLC and J.P. Morgan are acting as joint lead book-running managers for the offering, while Stifel is acting as a book-running manager.